Stages II-III Breast Cancer
Conditions
Brief summary
The purpose of this clinical trial is to test whether treatment of patients with breast cancer with the combination of Abraxane (nab-paclitaxel), Adriamycin (doxorubicin), and Cyclophosphamide prior to surgery is safe and results in good tumor response. Up to 24 patients may be enrolled in this study at the Mitchell Cancer Institute. All patients enrolling in this study will receive treatment with the combination of Abraxane, Adriamycin, and Cyclophosphamide.
Detailed description
This is a single center, open phase I dose escalation study with expansion cohort. The dose escalation part of the study is now closed and the highest tolerable dose of nab-paclitaxel (Abraxane) was assessed to be 100 mg/m2 in combination with doxorubicin (Adriamycin) and cyclophosphamide in patients with stages II-III breast cancer in the neoadjuvant setting. The initial phase I study objective was to primarily assess the safety of the drug combination, and to secondarily obtain preliminary data on the clinical efficacy of the combination. 25 patients were enrolled. The expansion cohort will enroll 15 additional patients. The purpose of the expansion cohort is to assess pathological complete response.
Interventions
IV administered over 30 minutes. 100 mg/m2 on days 1 and 8
DRUGdoxorubicin
50 mg/m2 every 3 weeks
DRUGcyclophosphamide
500 mg/m2 given every 3 weeks
Sponsors
Celgene Corporation
University of Utah
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically or cytologically proven adenocarcinoma of the breast stages II-III, according to the AJCC Staging Manual, 7th Edition, 2009 2. The following receptor status: Expansion: Triple negative (ER\<1%, PR\<1%, and Her-2/neu negative Phase 1 (closed): Negative Her-2/neu status 3. ECOG performance status 0 or 1 4. Negative pregnancy test 5. Normal cardiac function (ejection fraction \> lower limit of normal) as determined by MUGA or echocardiogram 6. ANC greater than or equal to 1,500/mm3; platelet greater than or equal to 100,000/mm3; hemoglobin greater than or equal to 9 gm/dL 7. Serum bilirubin levels less than or equal to 1.5 mg/dL 8. Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) less than or equal to 2.5 X upper limit of normal, alkaline phosphatase less than or equal to 2.5 X upper limit of normal. 9. Serum creatinine levels less than or equal to 1.5 mg/dL 10. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with nab-paclitaxel through 28 days after the last dose. Men should be advised to not father a child while receiving treatment with azacitidine or nab-paclitaxel. Appropriate methods of birth controls for women include oral or implanted contraceptives, intrauterine device (IUD), diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual partner and also based on the judgment of the investigator. 11. Female, greater than or equal to 19 years of age and any race.
Exclusion criteria
1. Concurrent therapy with any other non-protocol anti-cancer therapy 2. For Phase I patients only: Current therapy with hormone replacement therapy, or any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulators 3. Presence of neuropathy \> grade 2 (NCI-CTC version 3.0) at baseline 4. History of any other malignancy requiring active treatment 5. Clinically significant cardiovascular disease (e.g., hypertension \[BP \> 150/100\], myocardial infarction or stroke within 6 months, unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication 6. Currently active infection. 7. History of HIV infection or chronic hepatitis B or C. 8. The presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of the drugs in this protocol or place the subject at undue risk for treatment complications 9. Pregnancy or breast feeding 10. A history of a severe hypersensitivity reaction to nab-paclitaxel. 11. Any reason why, in the opinion of the investigator, the patient should not participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathologic complete response | 1 year |
| Type, incidence, severity, timing, seriousness and relatedness of adverse events and laboratory abnormalities | one year |
Secondary
| Measure | Time frame |
|---|---|
| Overall clinical response rate (OcRR) | one year |
Countries
United States
Outcome results
None listed